Physician profile
Luke E Lansman
NPI 1477110948
$1,391.12
in general payments reported to CMS, 2019-2025
26 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $166 · 2023: $501 · 2024: $355 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,225.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $293.31 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $194.08 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $128.09 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $109.97 | 2022-2025 | Fasenra, Farxiga, Airsupra |
| Amgen INC. | $109.28 | 2023-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.41 | 2023-2025 | Synjardy, Tradjenta, Jardiance |
| Ultragenyx Pharmaceutical INC. | $47.04 | 2022-2023 | |
| Abbvie INC. | $45.84 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $40.93 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.33 | 2023-2025 | Xifaxan |
| Kyowa Kirin, INC. | $29.81 | 2023 | Crysvita |
| Novartis Pharmaceuticals Corporation | $29.17 | 2023 | |
| Boston Scientific Corporation | $29.10 | 2024 | |
| Philips North America LLC | $23.06 | 2024 | (5044) Mcot |
| Actelion Pharmaceuticals US, INC. | $18.45 | 2023 | Uptravi, Opsumit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $18.35 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.20 | 2023 | Rexulti |
| Dexcom, INC. | $16.70 | 2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $16.33 | 2023 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $14.53 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $14.40 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $14.25 | 2024 | |
| Merck Sharp & Dohme LLC | $13.22 | 2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $13.07 | 2022 | |
| Sumitomo Pharma America, INC. | $11.51 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $8.69 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luke Lansman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.